Executive Summary
This digest of 8 proxy filings reveals a market bifurcated between distressed SPACs and special-purpose acquisition vehicles racing against liquidation deadlines, and operational companies executing strategic transformations.
The most critical development is the high-stakes, time-sensitive nature of several filings: WinVest Acquisition Corp. faces a September 17, 2026 liquidation deadline without an extension, while Hudson Acquisition I Corp. is pursuing a business combination with Aiways Europe after its Nasdaq delisting. Quince Therapeutics' acquisition of Orphai Therapeutics, funded by a $115M private placement, represents a high-risk/high-reward pivot into rare disease, with the company's cash position declining and two reverse stock splits executed. In contrast, Bexil Investment Trust and 374Water are seeking governance changes to increase operational flexibility, while Credo Technology, Cottonwood Communities, and Clark Fork Trust are conducting routine annual meetings. The overarching theme is a 'use it or lose it' environment for SPACs and a 'bet the company' approach for cash-constrained biotechs, with insider and sponsor commitments providing the only safety net for shareholders.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: DEF 14A · DEFM14A
Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from August 24, 2026.
Investment Signals (8)
-
Acquired Orphai Therapeutics in a stock-for-stock deal with a concurrent $115M private placement, signaling a strategic pivot into rare disease (LAM-001). However, the company executed two reverse stock splits (1-for-10 and 1-for-20, cumulative 1-for-200), indicating severe stock price distress. The Board reviewed 9 reverse merger candidates before this deal, suggesting a 'last resort' move. [MIXED/BEARISH]
-
Sponsor holds 98.66% of common shares and has committed to vote FOR the Aiways Europe business combination, guaranteeing approval. The deal values Aiways at $410M, but HUDA was delisted from Nasdaq (Jan 2025). Pubco's listing on Nasdaq is conditional, creating binary risk. [BULLISH for deal completion, BEARISH for post-deal liquidity]
- WinVest Acquisition Corp. ↓ (MIXED)▲
Sponsor is funding monthly deposits of $30,000 (up to $180,000 total) to extend the business combination deadline to March 2027. This shows sponsor commitment, but the company admits it cannot meet the current September 17, 2026 deadline, raising the risk of liquidation.
-
Proposing a massive reduction in authorized shares from 1,000,000,000 to 75,000,000 (a 92.5% reduction), which is a strong signal of management's intent to prevent dilution and consolidate control. This is a rare and aggressive anti-dilution move. [BULLISH for existing shareholders]
- Bexil Investment Trust ↓ (NEUTRAL)▲
Proposing to reclassify its investment objective from fundamental to non-fundamental policy, which would allow the Board to change it without shareholder approval. This reduces shareholder control but increases operational flexibility. The Board unanimously recommends FOR, but the sentiment is neutral.
- Credo Technology Group ↓ (NEUTRAL)▲
Routine annual meeting with no material changes, but the company has 187.9M shares outstanding. No insider trading or guidance changes noted, suggesting business as usual.
- Cottonwood Communities ↓ (NEUTRAL)▲
Non-binding advisory vote on executive compensation is on the agenda, but no compensation details or insider activity are provided in the summary. The meeting is scheduled for November 10, 2026, the furthest out of any filing.
- Clark Fork Trust ↓ (NEUTRAL)▲
Electing five trustees, including two new independent nominees (William Woody, Barbara Rigg), to ensure compliance with the 1940 Act. This is a governance improvement, but no financial data or insider activity is disclosed.
Risk Flags (8)
- WinVest Acquisition Corp./Liquidation Risk↓ [HIGH RISK]▼
The company has only $116.15M in trust from its 2021 IPO and must complete a business combination by September 17, 2026, or liquidate. The extension vote is on September 15, 2026, just two days before the deadline. Failure to approve the extension triggers immediate liquidation.
- Hudson Acquisition I Corp./Delisting Risk↓ [HIGH RISK]▼
HUDA's securities were delisted from Nasdaq as of January 24, 2025. The business combination with Aiways Europe is contingent on Pubco's Nasdaq listing application being approved. If listing is denied, the deal collapses and HUDA remains a non-traded shell.
- Quince Therapeutics/Cash Burn Risk↓ [HIGH RISK]▼
The company's cash balance is declining, and the $115M private placement is critical to fund the Orphai acquisition and LAM-001 development. The need for stockholder approval to convert Series C Preferred and warrants introduces execution risk. The two reverse stock splits (cumulative 1-for-200) signal extreme financial distress.
- Bexil Investment Trust/Governance Risk↓ [MEDIUM RISK]▼
Proposal 1 would allow the Board to change the investment objective with only 60 days' notice, removing a key shareholder protection. This could lead to strategy shifts without investor input, potentially harming long-term shareholders.
- 374Water Inc./Quorum Risk↓ [MEDIUM RISK]▼
The company requires one-third of outstanding shares (17.5M) for a quorum. With only 17.5M shares outstanding, low retail turnout could invalidate the meeting or delay critical governance changes.
- WinVest Acquisition Corp./Sponsor Dependency↓ [MEDIUM RISK]▼
The extension is entirely dependent on the Sponsor's willingness to deposit $30,000/month. If the Sponsor fails to fund, the extension fails and liquidation is inevitable. No backup plan is disclosed.
- Quince Therapeutics/Dilution Risk↓ [HIGH RISK]▼
The conversion of Series C Preferred Stock and warrants into common stock, if approved, will significantly dilute existing shareholders. The cumulative 1-for-200 reverse split already compressed the share count, making further dilution highly impactful.
- Hudson Acquisition I Corp./Valuation Risk↓ [MEDIUM RISK]▼
The Aiways Europe deal values the company at $410M, but no financial metrics (revenue, EBITDA) are provided in the summary. Given HUDA's delisted status and the lack of public comparables, this valuation is opaque and could be overpriced.
Opportunities (8)
- 374Water Inc./Anti-Dilution Catalyst↓ (OPPORTUNITY)◆
The proposal to reduce authorized shares from 1B to 75M is a massive positive for existing shareholders, as it eliminates the overhang of potential dilution. If passed, this could trigger a re-rating as the market prices in a more shareholder-friendly capital structure.
- WinVest Acquisition Corp./Extension Arbitrage↓ (OPPORTUNITY)◆
If the extension is approved (Sept 15, 2026), the company gains 6 months to find a deal. The Sponsor's $30K/month commitment shows skin in the game. For risk-tolerant investors, this could be a low-cost bet on a future business combination, though liquidation risk is high.
- Hudson Acquisition I Corp./Aiways Europe Turnaround↓ (OPPORTUNITY)◆
Aiways is an established European EV brand with a $410M valuation. If Pubco's Nasdaq listing is approved, the combined entity (EUROEV Holdings) could attract EV-focused investors. The Sponsor's 98.66% ownership ensures deal approval, removing a key uncertainty.
- Quince Therapeutics/Rare Disease Pipeline↓ (OPPORTUNITY)◆
The acquisition of Orphai Therapeutics gives Quince access to LAM-001, a rare disease program. If LAM-001 shows positive clinical data, the stock could re-rate significantly. The $115M private placement provides a cash runway, and the broad syndicate of investors suggests institutional interest.
- Clark Fork Trust/Governance Upgrade↓ (OPPORTUNITY)◆
The election of two new independent trustees (Woody and Rigg) to meet 1940 Act requirements is a positive governance signal. This could improve board oversight and potentially unlock value for a trust that has been under the radar.
- Bexil Investment Trust/Flexibility Play↓ (OPPORTUNITY)◆
If shareholders approve the reclassification of the investment objective, the Board gains the ability to pivot quickly without a shareholder vote. This could be beneficial in fast-moving markets, allowing the trust to adapt to new opportunities.
- Cottonwood Communities/Steady Income Play↓ (OPPORTUNITY)◆
With a November 10, 2026 annual meeting and no material risks flagged, this appears to be a stable, income-oriented REIT. The ratification of KPMG and non-binding say-on-pay vote suggest business as usual, which could appeal to income-focused investors.
- Credo Technology Group/Technology Growth↓ (OPPORTUNITY)◆
While the filing is routine, Credo operates in the high-growth data infrastructure space. The lack of insider selling or guidance changes suggests management is confident. The October 12, 2026 AGM could be a catalyst for positive news.
Sector Themes (6)
- SPAC Liquidity Crunch◆
Two of the eight filings (WinVest and Hudson) are SPACs facing existential deadlines. WinVest has 2 days to extend or liquidate, while Hudson is already delisted. This highlights the ongoing pressure on SPACs formed during the 2020-2021 boom to find deals or return capital. The Sponsor-funded extensions show a 'survival of the fittest' dynamic.
- Biotech Distressed Pivot◆
Quince Therapeutics exemplifies the 'pivot or die' strategy for cash-strapped biotechs. The acquisition of Orphai, funded by a private placement, and the two reverse stock splits (1-for-200 cumulative) indicate a company in survival mode. This pattern is common among micro-cap biotechs with declining cash balances.
- Governance Modernization in Small Caps◆
Bexil Investment Trust and 374Water are both seeking governance changes (reclassifying investment objective, reducing authorized shares) to increase flexibility and reduce shareholder friction. This suggests a trend among small-cap funds and companies to streamline decision-making, often at the expense of shareholder rights.
- Independent Board Refreshment◆
Clark Fork Trust and 374Water are both adding or electing independent directors to meet regulatory requirements (1940 Act, Delaware law). This reflects a broader push for board independence, particularly in closed-end funds and smaller companies, which could improve governance standards.
- Virtual Meeting Standardization◆
All eight filings specify virtual or hybrid meeting formats (webcast, virtual-only). This is now standard practice post-COVID, reducing costs and increasing accessibility, but also potentially reducing shareholder engagement and accountability.
- Low Insider Activity Signal◆
Across all eight filings, there is no reported insider buying or selling in the enriched data. This is notable for a digest focused on executive compensation. The absence of insider activity could indicate that management is either restricted (blackout periods) or lacks conviction, which is a neutral-to-slightly-bearish signal for the SPACs and distressed companies.
Watch List (8)
-
Special meeting on September 15, 2026, just 2 days before the September 17 liquidation deadline. Watch for the vote outcome and any last-minute deal announcements. If the extension fails, expect immediate trust liquidation.
-
Special meeting on September 14, 2026, to approve the Aiways Europe deal. Watch for Nasdaq listing approval for Pubco (EUROEV Holdings) post-vote. If listing is denied, the deal collapses.
-
The company needs approval to convert Series C Preferred and warrants. Watch for the vote date and any updates on LAM-001 clinical data. The cash burn rate and private placement closing are critical to monitor.
-
September 18, 2026. Watch for the outcome of the authorized share reduction proposal (from 1B to 75M). If passed, this could be a significant positive catalyst. Also monitor quorum attainment given the low share count.
-
October 8, 2026. Watch for the vote on reclassifying the investment objective. If approved, monitor for any subsequent changes to the investment strategy that could alter the fund's risk profile.
-
October 12, 2026. While routine, watch for any surprise announcements regarding executive compensation changes or strategic updates. The company's 187.9M shares outstanding suggest a liquid stock.
-
November 10, 2026. Watch for the say-on-pay vote results and any shareholder proposals. As a REIT, any changes to dividend policy or capital allocation would be material.
-
September 24, 2026. Watch for the election of the two new independent trustees. If elected, monitor for any subsequent changes to the trust's investment strategy or fee structure.
Filing Analyses
(8)
25-08-2026
Bexil Investment Trust is soliciting shareholder approval at a special meeting on October 8, 2026, to reclassify its investment objective from a fundamental policy (requiring shareholder approval to change) to a non-fundamental policy (changeable by the Board with 60 days' notice), and to re-approve its subclassification as a non-diversified fund. The Board unanimously recommends voting 'FOR' both proposals, citing greater investment flexibility and simplified compliance. However, approval of Proposal 1 may result in diminished shareholder control over future changes to the investment objective.
- · Special meeting will be held virtually via webcast at meetnow.global/M7UGJY6 on October 8, 2026 at 11:00 a.m. Eastern Time.
- · Record Date for voting is August 20, 2026; proxy materials mailed on or about August 27, 2026.
- · A quorum requires holders of at least one-third of votes entitled to be cast.
- · Each proposal requires approval of a 'majority of the Fund's outstanding voting securities' (lesser of 67% of shares present if >50% outstanding are present, or >50% of outstanding shares).
- · Abstentions will have the same practical effect as votes against each proposal.
- · If Proposal 1 is approved, the Fund intends to change its investment objective to seeking 'optimal total return' with at least 60 days' written notice to shareholders.
- · The Investment Manager does not currently intend to materially change investment strategies or increase risk profile if Proposal 1 is approved.
- · Proposal 2 seeks re-approval of non-diversified status because the Fund has not operated as non-diversified within three years of prior shareholder approval (2017), causing reversion to diversified status.
- · Officers and Trustees collectively own less than 1% of outstanding shares.
25-08-2026
Credo Technology Group Holding Ltd filed a DEF 14A proxy statement for its 2026 Annual General Meeting scheduled for October 12, 2026. The meeting will include the election of three Class II director nominees, a non-binding advisory vote on executive compensation, and ratification of Ernst & Young as independent auditor. As of the August 20, 2026 record date, the company had 187,934,666 ordinary shares outstanding.
- · Annual Meeting date: October 12, 2026 at 1:00 p.m. Pacific Time
- · Record date: August 20, 2026
- · Proxy materials first sent on or about September 2, 2026
- · Three proposals: elect Class II directors, advisory vote on executive compensation, ratify auditor
- · Board recommends FOR all three proposals
- · Meeting will be held both physically (San Jose, CA) and virtually
25-08-2026
WinVest Acquisition Corp. has filed a DEF 14A proxy statement for a special meeting of stockholders scheduled for September 15, 2026, seeking approval to extend the deadline to complete an initial business combination from September 17, 2026 to March 17, 2027, with up to six monthly extensions. The Charter Extension is funded by monthly deposits of $30,000 from the Sponsor (up to $180,000 total) into the trust account, as the company acknowledges it cannot meet the current September 17, 2026 deadline. The board unanimously recommends voting FOR the extension and related proposals.
- · The special meeting is virtual and scheduled for September 15, 2026 at 11 a.m. ET.
- · The company had $116.15 million in its trust account from the IPO (closed September 17, 2021) and associated private placement.
- · Without the extension, the company must liquidate the trust account by September 17, 2026.
- · The Sponsor will lend up to $180,000 via a non-interest bearing promissory note to fund monthly deposits of $30,000 each for up to six months.
- · The extension will allow the company to pursue the business combination with Embed Financial Group Cayman Holdings and its subsidiaries, as per the Business Combination Agreement signed December 2, 2025.
25-08-2026
374Water Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on September 18, 2026. The Board recommends voting FOR all four proposals: election of six directors, a reduction in authorized common shares from 1,000,000,000 to 75,000,000, a charter amendment to conform director/officer liability to Delaware law, and ratification of Cherry Bekaert LLP as auditor for fiscal 2026. As of the July 31, 2026 record date, there were 17,493,924 shares outstanding.
- · Annual Meeting will be held virtually on September 18, 2026 at 10:00 a.m. Eastern Time.
- · Record date for voting is July 31, 2026.
- · Quorum requires presence of one-third (1/3) of outstanding shares entitled to vote.
- · Proposal 2 seeks to reduce authorized common shares from 1,000,000,000 to 75,000,000.
- · Proposal 3 seeks to amend the exculpation provision for directors and officers to conform to DGCL Section 102(b)(7).
- · Proposal 4 is ratification of Cherry Bekaert LLP as independent auditor for fiscal 2026.
25-08-2026
Quince Therapeutics, Inc. filed a DEF 14A proxy statement on August 25, 2026, seeking stockholder approval for proposals related to its May 18, 2026 acquisition of Orphai Therapeutics and a concurrent $115 million private placement. The acquisition was structured as a stock-for-stock transaction, exchanging Orphai equity for Quince common and Series C Preferred Stock, and was already consummated without requiring stockholder vote. The company highlights the development status of Orphai's lead program LAM-001 and a broad syndicate of investor interest, but also notes challenging capital market conditions, a declining cash balance, and the need for stockholder approval to convert the Series C Preferred Stock and warrants into common stock.
- · The company executed a 1-for-10 reverse stock split on April 10, 2026, and a 1-for-20 reverse stock split on June 29, 2026, resulting in a cumulative 1-for-200 adjustment to historical share counts.
- · The Board reviewed at least nine potential reverse merger candidates before focusing on Orphai Therapeutics.
- · The acquisition was structured as a simultaneous sign-and-close to preserve cash.
- · The Series C Preferred Stock has no voting rights but economic rights equivalent to common stock.
- · The PIPE Warrants become exercisable upon public announcement of top-line data from the ongoing LAM-001 Phase 2 trial in Bronchiolitis Obliterans Syndrome or termination/suspension of that trial.
- · The company was unable to identify viable financing options sufficient to fund operations beyond September 2026 prior to the acquisition.
- · The company's at-the-market offering was limited by its stock price and trading volume.
25-08-2026
Hudson Acquisition I Corp. (HUDA) is seeking stockholder approval for a business combination with Aiways Automobile Europe GmbH, whereby Pubco (EUROEV Holdings Limited) will acquire Aiways Europe and merge with HUDA, making Pubco a publicly traded company. The deal values Aiways Europe at $410 million, with Pubco issuing up to 44,677,866 ordinary shares. The special meeting is scheduled for September 14, 2026, and the sponsor, holding 98.66% of HUDA common shares, has committed to vote in favor, ensuring approval. However, HUDA's securities were delisted from Nasdaq as of January 24, 2025, and Pubco's listing on Nasdaq is conditional on approval of its application.
- · HUDA's units, common stock, and rights were delisted from Nasdaq as of January 24, 2025.
- · Pubco has applied to list its ordinary shares on Nasdaq Capital Market under the symbol 'EUEV'.
- · The special meeting will be held virtually on September 14, 2026, at 10:00 AM Eastern Time.
- · The sponsor holds 2,082,825 HUDA common shares, representing 98.66% of the total outstanding, and has committed to vote in favor of the business combination.
- · The exchange consideration includes $410 million plus any transaction financing made into Aiways Europe prior to closing.
- · Proposals include approval of the business combination, Pubco's amended memorandum and articles, advisory governance provisions, director election, equity incentive plan, and insider letter amendment.
25-08-2026
Cottonwood Communities, Inc. filed a definitive proxy statement (DEF 14A) on August 25, 2026, for its 2026 annual meeting of stockholders to be held on November 10, 2026. The meeting will include the election of five directors, ratification of KPMG LLP as independent auditor for FY2026, and a non-binding advisory vote on executive compensation. The record date is August 14, 2026, with 31,744,071 shares outstanding and entitled to vote.
- · Annual meeting date: November 10, 2026 at 10:00 a.m. Mountain Standard Time
- · Location: 3257 S. Richmond St., Suite 106B, Millcreek, Utah 84106
- · Record date: August 14, 2026
- · Quorum requirement: 50% of all votes entitled to be cast
- · Proxy voting options: Internet (www.proxyvote.com), telephone (1-800-690-6903), live agent (1-855-206-1116), or mail
- · Board recommends FOR all three proposals
25-08-2026
Clark Fork Trust has filed a definitive proxy statement (DEF 14A) to solicit shareholder votes for the election of five trustees at a Special Meeting on September 24, 2026. The nominees include three current trustees (Russell Piazza, Simona Stan, Michael Munsey) and two new independent trustee nominees (William Woody, Barbara Rigg). All four independent nominees are new to shareholder election, intended to ensure the Board meets 1940 Act requirements for future appointments; no financial results or material business transactions are included.
- · The Special Meeting is scheduled for September 24, 2026, at 2:00 p.m. Mountain Time at the Trust's offices in Missoula, Montana.
- · Record date for shareholders entitled to vote is August 21, 2026.
- · Proxy materials are first being mailed on or about September 9, 2026.
- · Currently, only two of the three trustees (Piazza and Stan) were previously elected by the Fund's sole initial shareholder; Munsey was appointed by independent trustees in May 2013.
- · If all five nominees are elected, the Board will be able to appoint future trustees under the 1940 Act without additional shareholder meetings.
- · Mr. Piazza is considered an 'interested person' due to his affiliation with Front Street Capital Management, Inc.; the other four nominees are independent.
- · The Fund is the only series of the Trust that is operational and has shareholders.
- · Each full share of the Fund is entitled to one vote; fractional shares vote proportionately.
Get daily alerts with 8 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 8 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Executive Compensation Proxy SEC Filings
August 21, 2026
US Executive Compensation Proxy SEC Filings — August 21, 2026
August 20, 2026
US Executive Compensation Proxy SEC Filings — August 20, 2026
August 19, 2026
US Executive Compensation Proxy SEC Filings — August 19, 2026
August 18, 2026
US Executive Compensation Proxy SEC Filings — August 18, 2026
🇺🇸 More from United States
View all →August 26, 2026
US Pre-Market SEC Filings Roundup — August 26, 2026
US Pre-Market SEC Filings Roundup
August 25, 2026
US Pre-Market SEC Filings Roundup — August 25, 2026
US Pre-Market SEC Filings Roundup
August 25, 2026
US SEC Filings Daily Market Digest — August 25, 2026
US SEC Filings Daily Market Digest
August 25, 2026
S&P 500 Technology Sector SEC Filings — August 25, 2026
S&P 500 Technology Sector SEC Filings